Chronic Subdural Medical Management.
Chronic subdural hematomas (cSDHs) that are asymptomatic or have minimal symptoms have become more prevalent, with an increased rate of detection with neuroimaging in the setting of an aging population and increasing use of anticoagulants. These cSDHs have been known to spontaneously resolve, and subsequent efforts have been made to study the role of nonoperative initial medical management strategies in these patients. Current and potential strategies for the medical management of cSDH are discussed.
Department of Neurology, Columbia University Medical Center, 177 Fort Washington Avenue, Milstein Building 8GS-300, New York, NY 10032, USA. Electronic address: dr2753@cumc.columbia.edu.
David
D
Roh
Department of Neurology, Columbia University Medical Center, 177 Fort Washington Avenue, Milstein Building 8GS-300, New York, NY 10032, USA.
Michael
M
Reznik
Department of Neurology, Columbia University Medical Center, 177 Fort Washington Avenue, Milstein Building 8GS-300, New York, NY 10032, USA.
Jan
J
Claassen
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000933:Antifibrinolytic Agents / Q000627:therapeutic use; D020200:Hematoma, Subdural, Chronic / Q000150:complications / Q000175:diagnosis / Q000628:therapy*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D007249:Inflammation / Q000150:complications / Q000517:prevention & control; D012640:Seizures / Q000150:complications / Q000517:prevention & control; D016896:Treatment Outcome
D000305:Adrenal Cortex Hormones; D000806:Angiotensin-Converting Enzyme Inhibitors; D000933:Antifibrinolytic Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors
Angiotensin-converting enzyme inhibitor; Antiepileptic drug; Antifibrinolytic; HMG-CoA reductase inhibitor; Medical management; Nonoperative; Steroid; Subdural hematoma